Navigation Links
Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
Date:8/18/2011

MEDFORD, N.Y., Aug. 18, 2011 /PRNewswire/ -- Richard Larkin, Chief Financial Officer of Chembio Diagnostics, Inc. (OTCQB: CEMI) (OTC.BB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, is among the recipients of the "2011 CFO of the Year" award from Long Island Business News (LIBN).  A total of 27 CFOs were awarded the honor this year.  Among the honorees, Mr. Larkin was one of two CFOs of a public company with revenue under $50 million.    

Mr. Larkin was awarded the honor by LIBN judges, who chose him based on the critical role he has played in Chembio's success.  The award program acknowledges "the outstanding performance, contributions and accomplishments of the financial professionals guiding Long Island's companies and organizations."  Mr. Larkin oversees Chembio's financial activities and information systems, and has been the Chief Financial Officer since September 2003.

Mr. Larkin and the other 2011 recipients will be honored at a special gala at The Crest Hollow Country Club in Woodbury, NY on the evening of Thursday, September 22.

Larry Siebert, Chairman and Chief Executive Officer of Chembio, commented: "Rich Larkin has been a tremendous asset to our entire organization since he joined us in 2003, and has played a critical role in the growth of our company.  We would like to thank the judges at Long Island Business News for acknowledging Richard, and congratulate the other recipients of the award this year."

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 130 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, and actual results may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:
Company Contact:
Susan Norcott
631-924-1135 x125  
snorcott@chembio.com

Investor & Public Relations
The Investor Relations Group
212-825-3210
Adam S. Holdsworth
aholdsworth@investorrelationsgroup.com


'/>"/>
SOURCE Chembio Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Declares Quarterly Cash Dividend
2. Enigma Diagnostics and GSK Announce Collaboration on Assay Development and Commercialization of Enigmas ML Platform
3. Caliper Life Sciences to Present at the Leerink Swann Life Science Tools & Diagnostics Roundtable
4. Quest Diagnostics to Unveil Extensions to its Womens Health and Personalized Medicine Test Offerings at the 2011 AACC Annual Meeting and Clinical Lab Expo
5. Ortho Clinical Diagnostics Launches VITROS® 4600 Chemistry System for Mid- to High-Volume Laboratories
6. Ortho Clinical Diagnostics Launches VITROS 4600® Chemistry System for Mid- to High-Volume Laboratories
7. BD Diagnostics Hires Leading Infectious Disease Diagnostics Expert to Strengthen New Product Pipeline
8. Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
9. Medical Devices & Diagnostics Equipments in India
10. Reportlinker Adds HIV Diagnostics Market in India
11. DeviceSpace Campaign Features Medical Device and Diagnostics Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
Breaking Medicine News(10 mins):